GET DAILY SIGNALSWhy Is KORU Medical Systems (KRMD) Stock Down -2.17% Today?
Key Takeaways
- KORU Medical Systems (KRMD) traded at $3.61, down $0.08 or 2.17%, from the prior session's close of $3.69.
- The decline extends a two-day retracement that followed a 23.10% single-session surge on Nov. 11 after a third-quarter earnings beat and a raised full-year revenue range.
- No new company announcement, SEC filing, financing or analyst action has been identified for today's session; the pullback appears to be post-earnings profit-taking.
- Biotech and small-cap proxies were soft, with the XBI biotech ETF down 1.61% and the Russell 2000 proxy IWM off 0.37%, while the medical-devices ETF IHI gained 0.90%.
- Early-session volume was unusually thin at roughly 16,000 shares versus a three-month average near 225,000, leaving the tape sensitive to modest order flow.
- News Significance Score: 6/100 – no fresh news and a decline almost exactly the size of the stock's typical daily swing.
- Traders are watching whether the $3.50–$3.55 zone holds and whether the pending deferoxamine FDA decision lands before year-end.
- Investors can dig deeper into the company's Price Targets, Earnings history and Forecast pages for added context on the setup.
- For real-time strategy ideas across thousands of symbols, explore the curated Trending AI Robots section.
KORU Medical Extends Its Post-Earnings Pullback
KORU Medical Systems (KRMD) is a Mahwah, New Jersey-based medical technology company that designs and sells the Freedom Syringe Infusion System — pumps, precision flow-rate tubing and needle sets used for large-volume subcutaneous drug delivery, largely in patients' homes. The company also supplies devices to pharmaceutical partners for clinical trials and commercial drug launches, and carries a market capitalization of roughly $160 million.
In today's session the stock is trading at $3.61, down $0.08, or 2.17%, from the previous close of $3.69. That places the shares about 7% below their Nov. 11 closing level of $3.89. No verified corporate, regulatory or analyst catalyst was found for the current decline, which follows an outsized two-day rally and a subsequent round of profit-taking.
The Earnings Beat That Still Frames the Trade
KORU reported third-quarter results after the close on Nov. 10, and the numbers were stronger than expected across the income statement. Revenue came in at $11.6 million, up 11% year over year and ahead of the roughly $11.3 million consensus, while adjusted earnings of $0.02 per share compared with expectations for a small loss. Gross margin expanded to 65.2% from 60.2%, and the company posted positive net income and adjusted EBITDA for a second consecutive quarter.
Management raised the low end of its full-year 2026 revenue guidance to $48.0–$48.5 million, implying 17%–18% growth, and lifted its gross-margin and year-end cash targets. Shares jumped 23.10% the next session on volume roughly double the norm. The bullish read was that profitability is arriving faster than modeled while the recurring patient base keeps compounding. The offsetting detail: quarterly growth of 11% decelerated from the first half, international revenue fell 17% on a reported basis because of prior-year distributor timing, and pharma services revenue slipped 27%. Analysts also trimmed targets — one covering firm cut its price objective to $4.50 from $5 while keeping a neutral stance — which capped the rally.
No Fresh Catalyst, Just Digestion
No verified news or fundamental catalyst found for today's move. With the earnings event absorbed and no new filing, contract announcement or rating change on the tape, the most defensible assessment is that the stock is digesting its sharp re-rating. After a 23% gap higher, a two-session retracement of roughly 7% from the peak is consistent with short-term holders locking in gains, particularly in a micro-cap where daily swings of 2% or more have occurred in about a third of the last 60 sessions. Thin early-session liquidity — only about 16,000 shares had changed hands shortly after the open — makes that kind of drift easier to produce than on a normal-volume day.
Sector and Market Backdrop
Broader conditions were not supportive of high-beta healthcare. The XBI biotech ETF fell 1.61% and the IWM small-cap benchmark slipped 0.37%, while the S&P 500 proxy eased 0.20%. Notably, the IHI medical-devices ETF rose 0.90%, so KORU underperformed its closest product-market peers and moved in the direction of the speculative-biotech complex instead. That pattern points to positioning flow rather than a sector-wide reassessment of subcutaneous infusion demand.
Market Context and Trading Activity
Volume is running well below average for the time of day, in contrast with the 503,700 shares traded on Nov. 11 and 352,200 on Nov. 12 — both elevated relative to a three-month average near 225,000. The intraday range of $3.51 to $3.72 is wide for a 2% decline, evidence of a loose order book. Technically, the stock remains roughly 15% above its 50-day moving average near $3.13 and well off its 52-week low of $2.86, so today's dip looks like consolidation inside an uptrend rather than a breakdown. The $3.50 area, which contained today's low, is the first level traders are monitoring; the post-earnings high of $4.07 remains the near-term resistance.
News Significance Score
The score runs from 0 to 100, where 0 represents no meaningful news and a move that is entirely normal for the stock, and 100 represents transformative news paired with an extreme, rare price change. KORU Medical earns 6 out of 100.
That reflects the absence of any verified news for this session, offset only by the fact that the company remains inside a genuinely material post-earnings story. Today's 2.17% decline was essentially identical to the stock's average absolute daily move of about 2.1% over the last 60 sessions, and moves of that size or larger occurred in 17 of those sessions. With no new information and routine price behavior, both halves of the calculation stay weak, producing a low combined score.
What Comes Next for KORU Medical Systems
The next hard catalyst is fourth-quarter and full-year 2026 results, expected in the first quarter of 2027, when management has guided to high-teens revenue growth and is expected to issue formal 2027 guidance alongside gross-margin detail. Investors will also watch the FDA's review of the company's 510(k) application for deferoxamine, which management has said could clear in the near term but which remains in agency hands, and the planned Freedom360 next-generation pump submission targeted for the end of 2026.
On the commercial side, the ramp of RYSTIGGO-related specialty pharmacy volume and the newly signed European and African distribution agreements are the clearest near-term revenue levers, with initial orders already shipped. Risks include the company's dependence on a concentrated group of pharmaceutical partners, the lumpy timing of clinical-trial device orders, continued deceleration in reported growth, and limited disclosure on the oncology pipeline until the first half of 2027. With a consensus rating of Buy and average price objectives well above the current quote, sentiment remains constructive, but execution against guidance now matters more than narrative.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, and only the strongest performers under prevailing market conditions earn a place in its curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup rotates as conditions change. Reviewing the current leaders can help traders compare approaches and find strategies aligned with their own risk parameters before deploying capital.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KRMD in upward trend: 10-day moving average crossed above 50-day moving average on November 04, 2026
The 10-day moving average for KRMD crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on KRMD as a result. In 88 of 111 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for KRMD just turned positive on October 12, 2026. Looking at past instances where KRMD's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.
KRMD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRMD advanced for three days, in 178 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 144 of 167 cases where KRMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for KRMD moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 26 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
KRMD broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.904) is normal, around the industry mean (4.964). KRMD has a moderately low P/E Ratio (-77.250) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.770) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.292) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. KRMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 83 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the design, manufacture, and market of proprietary medical devices
Industry PharmaceuticalsOther
Advertisement